The Global Cytokine Release Syndrome Management Industry is on track for significant growth, driven by the rising prevalence of conditions that can trigger CRS. According to a recent analysis by Future Market Insights (FMI), the market is expected to reach US$23.32 billion in 2023 and climb to US$42.21 billion by 2033, reflecting a Compound Annual Growth Rate (CAGR) of 6.7%.
The burgeoning need for innovative therapies is evident in mantle cell lymphoma (MCL), where patients face significant unmet needs. The development of novel therapies has shown promising efficacy, emphasizing the urgency to explore synergistic approaches combining targeted therapy and immunotherapy. Such synergies are expected to deliver rapid and enduring responses to treatment while minimizing side effects.
The evolving landscape of cancer treatment sees a continuous rise in cancer rates and an expanding array of options for managing CRS. Companies like Harpoon Therapeutics, Inc., are at the forefront of this innovation, currently engaged in clinical trials for novel T-cell engagers. Notably, the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans recently featured updated interim data from the Phase 1 clinical trial of HPN217 in relapsed/refractory multiple myeloma (RRMM). Developed on Harpoon’s proprietary TriTAC® platform, HPN217 targets B-cell maturation antigens (BCMA), harnessing patients’ own immune cells to target tumors effectively.
Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16438
FDA approvals of various therapeutics and drugs have further enhanced the market. Further studies and tests funded by the government will increase awareness of CRS management by clinical professionals. For instance, mosunetuzumab-axgb (Lunsumio; Genentech) was approved by the FDA for treating adults with R/R follicular lymphoma. As of July 2022, mosunetuzumab had been granted priority review by the FDA for the treatment of R/R FL. High and durable responses were demonstrated in the phase 2 GO29781 study (NCT02500407), which supported the decision. The continued approval of this product is dependent on a confirmatory trial verifying clinical benefit since this is an accelerated approval.
Key Takeaways from the Global Cytokine Release Syndrome Management Industry Study
- Globally, the cytokine release syndrome management market is expected to reach US$ 23.32 billion by 2023.
- Hospitals for cytokine release syndrome management are expected to grow 32% market share between 2023 and 2033.
- The market for Tumour Necrosis Factor-TNF is projected to grow by 2.9% from 2023 to 2033.
- Cytokine release syndrome management in North America expanded with a market share of 17% during the forecast period.
- According to forecasts, the arthritis therapeutics market will accumulate a share of 19% over the next few years.
“Advances in immunotherapies, the approval of new drugs, and CAR T-cell therapies are expected to further accelerate the growth of the cytokine release syndrome management market.” comments a Future Market Insights analyst.
Global Cytokine Release Syndrome Management Industry Competitive Landscape
The development of innovative diagnostic techniques is becoming increasingly important for companies, which will probably lead to several firms expanding their product lines, acquiring other companies, or merging their companies shortly, as many are likely to focus on developing new diagnostic techniques.
- Kite announced that the Food and Drug Administration (FDA) has approved the addition of prophylactic corticosteroids to the prescribing information for Yescarta®. The label on Yescarta includes information to guide physicians in managing and possibly preventing side effects associated with chimeric antigen receptor (CAR) T-cell therapies. To maximize the chances of CAR T-cell therapy being beneficial to as many patients as possible, Kite has been working closely with physicians since Yescarta’s first approval in 2012. CAR T therapy research is also focused on expanding into new diseases and early treatment lines, while continuously enhancing the safety and efficacy of existing treatments.
- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., reported stable response rates among 6 patients with relapsed/refractory AL amyloidosis using NXC-201. Six relapsed/refractory AL amyloidosis patients treated with NXC-201 have shown 100% complete response. Using clinical cancer research, 100% complete responses were observed; 100% organ responses were observed; and at 5.2 months, the duration of response was still unknown, resulting in an average reduction of 65% (2,656 pg/mL) in NT-proBNP from baseline. There was no grade 4 Cytokine Release Syndrome. ICANS neurotoxicity was not observed; NYHA stage improved by 2 stages.
Key Companies Profiled:
- Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Bayer AG
- Biocon
- AbbVie Inc.
- Johnson & Johnson Private Limited
- Incyte Corporation
- Swedish Orphan Biovitrum
- Genentech
Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/16438
Key Segments Profiled in the Global Cytokine Release Syndrome Management Industry Survey?
By Cytokine Type:
- Tumor Necrosis Factor-TNF
- Interleukins-II
- Interferons-IFN
- Epidermal Growth Factor-EGF
By Therapeutic Application:
By Biomarker Type:
- Interleukin-10
- Interferon Gamma
- Interleukin-6
- Ferritin
- Cluster of Differentiation-163
By Route of Administration:
- Oral
- Intravenous
By End User:
- Hospitals
- Specialty Clinics
- Others
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
